AMVUTTRA® (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by hATTR amyloidosis in adults.

AMVUTTRA is a prescription medicine that treats the: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, …

AMVUTTRA is a prescription medicine that treats the: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, …

AMVUTTRA is a prescription medicine that treats the: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, …

Access educational resources about treatment with AMVUTTRA for you and your family. See Important Safety Information on low vitamin A levels.

AMVUTTRA is a prescription medicine that treats the: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, …

Explore how AMVUTTRA® (vutrisiran), a prescription medicine, works in adults. See safety info on low vitamin A levels and PI.

AMVUTTRA is a prescription medicine that treats the: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, …

Patients treated with AMVUTTRA showed significant improvement in nerve function and quality of life at 9 months, and continued to improve throughout an 18-month study of 164 adult patients, …

AMVUTTRA is a subcutaneous injection that can be given in the thigh, abdomen, or upper arm with a prefilled syringe. AMVUTTRA may cause reactions at the injection site such as bruising, …